Healthcare in the GCC continues to undergo major transformation with the introduction of government reforms, a shifting demographic and mandatory health insurance. These factors along with increased private sector participation and an ongoing infrastructure boom are poised to drive further…
Amira Younes of AbbVie UAE examines how the COVID-19 pandemic highlighted the need for new ways of thinking about delivering regulatory effectiveness and efficiency in the region, and for flexibility…
The latest news from the Saudi healthcare and life science industry, including how the implementation of COVID-19 measures have helped reduce the prevalence of MERS-CoV in the country, regulatory approval…
The Saudi Food and Drug Authority (SFDA) has joined the Pharmaceutical Inspection Co-operation Scheme (PIC/S), aimed at harmonising inspection procedures worldwide. Through PIC/S membership the SFDA looks to continue bolstering…
Prof. Ayman Abdo, SVP of Saudi private healthcare cornerstone Fakeeh Care Group, outlines the group’s large range of activities, encompassing a network of hospitals, home care services, ambulance systems, and…
Fadi Ghanayem, Managing Director for Saudi Arabia and Caucasus, Central Asia, Iran and Mongolia (CCAIM) at French diagnostics firm BioMérieux discusses the remarkable growth he has witnessed in Saudi Arabia…
Over the past three years, Sanofi has significantly expanded its presence in the GCC region, launching 40-50 new products, including treatments for rare diseases and advancements in immunology, diabetes management,…
Some of the most significant stories coming out of Saudi Arabia’s dynamic pharmaceutical industry, including Spanish firm Cinfa’s decision to reinforce its presence in the country, how Saudi and other…
Halal pharmaceuticals, or medicines produced according to Islamic dietary laws, presented a global market worth some USD 100 billion in 2019, yet much of halal pharmaceuticals’ potential remains untapped. In…
As the GCC’s largest market, Saudi Arabia, with its growing population, strong healthcare infrastructure and government commitment to developing the economy beyond oil through its Vision 2030, is increasingly attractive…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
Under Saudi Arabia’s Vision 2030 plan, the country has been activating the private sector’s participation in its healthcare transformation, advancing the public-private partnership (PPP) model to step up the rollout…
While international pharma has long been present in Saudi Arabia, the ambitious goals outlined in the country’s Vision 2030 economic transformation plan have encouraged companies to reinforce their commitment to…
See our Cookie Privacy Policy Here
